Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

17.86 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

20 21 Next >

Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics

December 13, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting ↗

December 09, 2022

Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study

Via Benzinga

Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases

December 09, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda's Dengue Vaccine Candidate Under FDA Priority Review ↗

November 23, 2022

Via Benzinga

Takeda Posts Lower 1H Profit, Lifts FY22 Outlook ↗

October 27, 2022

Via Benzinga

Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union

December 08, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing

December 06, 2022

From Singapore Economic Development Board (EDB)A*STAR

Via ACN Newswire

Are Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities? ↗

November 30, 2022

Tech layoffs are in the news, but life sciences companies seem to be doing better.

Via The Motley Fool

Stocks That Hit 52-Week Lows On Wednesday ↗

October 19, 2022

On Wednesday, 200 companies hit new 52-week lows.

Via Benzinga

Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids ↗

October 05, 2022

Via Benzinga

Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease ↗

November 29, 2022

The company says it plans soon to present Phase 2 results and its Phase 3 study design.

Via Investor's Business Daily

Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration

November 22, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved ↗

November 22, 2022

This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result...

Via Benzinga

Why Puma Biotechnology's Shares Jumped 20% on Monday ↗

November 21, 2022

It may have benefited from positive news about another company's drug candidate.

Via The Motley Fool

Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings ↗

November 17, 2022

Via Benzinga

Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US

November 17, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

2 Beaten-Down Dividend Stocks That Haven't Been This Cheap In More Than a Decade ↗

November 16, 2022

Is now the time to load up on these high-yielding investments?

Via The Motley Fool

European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies

November 11, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Why Denali Therapeutics' Stock Rose 6.6% on Wednesday ↗

November 02, 2022

The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close.

Via The Motley Fool

Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast

October 27, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

7 Dividend Stocks to Sell Pronto Before a Painful Downturn ↗

October 24, 2022

Investors may find many dividend stocks to sell, considering returns from the risk-free U.S. Treasury Bills often exceed their yield.

Via InvestorPlace

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗

October 20, 2022

Despite enthusiasm in some camps, the risk of potential cures clouds market projections.

Via Investor's Business Daily

Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy

October 20, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Earnings Scheduled For October 27, 2022 ↗

October 27, 2022

Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.

Via Benzinga

3 High-Yielding Dividend Stocks Near Their 52-Week Lows ↗

October 19, 2022

These stocks all pay far higher than the S&P 500 average dividend yield of 1.8%.

Via The Motley Fool

Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries

October 14, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease

October 05, 2022

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,...

Via FinancialNewsMedia

Topics Cannabis

U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

October 05, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Strengthening Healthcare Systems to Meet Patients’ Need for Plasma-Derived Therapies

September 29, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer ↗

September 21, 2022

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.